Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Olema Pharmaceuticals (OLMA) Current Assets (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Current Assets data on record, last reported at $513.2 million in Q1 2026.

  • On a quarterly basis, Current Assets rose 29.39% to $513.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $513.2 million, a 29.39% increase, with the full-year FY2025 number at $515.5 million, up 17.56% from a year prior.
  • Current Assets reached $513.2 million in Q1 2026 per OLMA's latest filing, roughly flat from $515.5 million in the prior quarter.
  • Over the last five years, Current Assets for OLMA hit a ceiling of $515.5 million in Q4 2025 and a floor of $171.5 million in Q2 2023.
  • A 5-year average of $302.0 million and a median of $266.5 million in 2023 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: dropped 29.91% in 2023, then soared 64.52% in 2024.
  • Tracing OLMA's Current Assets over 5 years: stood at $208.9 million in 2022, then increased by 27.58% to $266.5 million in 2023, then skyrocketed by 64.52% to $438.5 million in 2024, then rose by 17.56% to $515.5 million in 2025, then decreased by 0.43% to $513.2 million in 2026.
  • Business Quant data shows Current Assets for OLMA at $513.2 million in Q1 2026, $515.5 million in Q4 2025, and $334.3 million in Q3 2025.